REG - Dr. Martens PLC - Directorate change

Dr MartensAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260527:nRSa7612Fa&default-theme=true

RNS Number : 7612F  Dr. Martens PLC  27 May 2026

27 May 2026

 

Dr. Martens plc

DIRECTORATE CHANGE

Dr. Martens plc ('Dr. Martens' or 'the Company'), the iconic British footwear
brand with a global presence, announces that Lynne Weedall, Senior Independent
Director and Chair of the Remuneration and Nomination Committees, has informed
the Board of her intention to step down at the conclusion of the 2026 Annual
General Meeting ('AGM') on 15 July 2026 after almost six years on the Board.
Lynne will therefore not seek re-election at the 2026 AGM.

A thorough succession process to appoint Lynne's replacement on the Board is
well progressed and a further announcement will be made in due course.

Paul Mason, Chairman of Dr. Martens, said: "On behalf of the Board, I would
like to thank Lynne for her significant contributions since the Company's IPO
in 2021. She has brought sound judgement, constructive challenge and a strong
governance mindset, and I have greatly valued her counsel and support."

 

NOTES

 

1.     This announcement is made pursuant to UK Listing Rule 6.4.6R.

 

Enquiries

Investors and analysts
 

Bethany Barnes, Director of Investor Relations and Corporate Communications

Bethany.Barnes@drmartens.com (mailto:Bethany.Barnes@drmartens.com)

+44 7825
187465

 

Paul Rolling, Head of Secretariat

Paul.Rolling@drmartens.com (mailto:Paul.Rolling@drmartens.com)

 

Press enquiries:

Rob Greening / Ludo Baynham-Herd

drmartens@client.sodali.com

+44 207 250 1446

 
 

 

About Dr. Martens

Dr. Martens is an iconic British footwear brand founded in Northamptonshire,
England. Its first silhouette, the 1460 boot - named after the date it was
produced - rolled off the production line on 1st April 1960. Originally chosen
by workers for their air-cushioned comfort and durability, "Docs" or "DM's"
were later adopted by musicians and subcultural pioneers who took them from
the street to the global stage.

Over six decades later, Dr. Martens operates in more than 60 countries and
employs around 3,600 people. The company continues to honour the brand's
heritage through its 'Made in England' footwear, manufactured at its original
Northamptonshire factory, while meeting global demand from multiple
high-quality production sites across Asia. All our products are made with an
unwavering commitment to craft, combined with innovative techniques.

A brand built to put a bounce in the step of those who stand out from the
crowd, Dr. Martens is available through Direct-to-Consumer (Retail and
Ecommerce) and Wholesale channels. The brand's collections range from its
Original silhouettes - The Icons such as the 1460 boot, 1461 shoe, 2976
Chelsea boot, and Adrian loafer - to modern franchises like the Zebzag, Buzz,
and Lowell. The lineup also includes an extensive range of sandals, a
dedicated Kids collection, and a curated selection of bags, small leather
goods, and accessories.

Every Dr. Martens product reflects craftsmanship, heritage, timeless style,
comfort, and versatility. Having transcended generations, the brand stays as
relevant today as it was at its inception. Its signature yellow welt
stitching, grooved sole edges, and scripted "With Bouncing Soles" heel loops
remain iconic symbols recognised around the world.

Dr. Martens plc (DOCS.L) is listed on the main market of the London Stock
Exchange and is a constituent of the FTSE 250 index.

For more information, visit www.drmartens.com or www.drmartensplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOASEFFIMEMSEFI



            Copyright 2019 Regulatory News Service, all rights reserved